'COVID-19 vaccine to be available in India by January if...,' says Serum Institute CEO Poonawalla
There are no immediate concerns pertaining to Covishield, says Adar Poonawalla, Serum Institute of India
Serum Institute of India aims to initially manufacture about 60-70 million doses of its experimental vaccine Covishield
A safe and effective vaccine against novel coronavirus may be available in India by January 2021, says Adar Poonawalla, chief executive officer (CEO), Serum Institute of India. Pune based drugmaker joined hands with British-Swedish pharma major AstraZeneca to produce the coronavirus vaccine for low-and-middle income countries, developed by University of Oxford. Dubbed as Covishield, the vaccine is currently in the Phase II/III clinical trial in the country. "Based on the success of the trials in India and the United Kingdom, and if approvals from regulatory bodies are in place in time, then we can expect the vaccine to be available in India by January 2021, only if its proven immunogenic and efficacious, Poonawalla said in an interview with Mint.